(Q38049899)

27 August 2017

title

The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB. (English)

1 reference

27 August 2017

0 references

0 references

Anders E Lilja

1

1 reference

27 August 2017

Peter W Mason

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

3 October 2012

1 reference

27 August 2017

number of pages

11

1 reference

inferred from page(s)

published in

Vaccine

1 reference

27 August 2017

volume

30

1 reference

27 August 2017

issue

49

1 reference

27 August 2017

page(s)

6980-6990

1 reference

Cytomegalovirus immune evasion.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Antiviral strategies to combat cytomegalovirus infections in transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

How we treat cytomegalovirus in hematopoietic cell transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy--a case-control study of the outcome in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cytomegalovirus cell tropism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cytomegalovirus reinfection in young children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Acquisition of donor strains of cytomegalovirus by renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cytomegalovirus reinfections in healthy seroimmune women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Maternal immunity and prevention of congenital cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

The outcome of congenital cytomegalovirus infection in relation to maternal antibody status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cytomegalovirus (CMV) viremia and the CD4+ lymphocyte count as predictors of CMV disease in patients infected with human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Infection in organ-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Pathogenesis of murine cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Animal models of congenital cytomegalovirus infection: an overview of progress in the characterization of guinea pig cytomegalovirus (GPCMV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Rhesus cytomegalovirus a nonhuman primate model for the study of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Structure and formation of the cytomegalovirus virion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Coding potential of laboratory and clinical strains of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

In silico pattern-based analysis of the human cytomegalovirus genome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Three-dimensional visualization of tegument/capsid interactions in the intact human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Biochemical and structural characterization of the capsid-bound tegument proteins of human cytomegalovirus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

RNAs are packaged into human cytomegalovirus virions in proportion to their intracellular concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus entry into cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Structure, composition and heparin binding properties of a human cytomegalovirus glycoprotein complex designated gC-II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

The human cytomegalovirus UL100 gene encodes the gC-II glycoproteins recognized by group 2 monoclonal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

The cytoplasmic tail of glycoprotein M (gpUL100) expresses trafficking signals required for human cytomegalovirus assembly and replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Entry of herpesviruses into mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Crystal structure of glycoprotein B from herpes simplex virus 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Expression, purification, and characterization of a soluble form of human cytomegalovirus glycoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Structure of a trimeric variant of the Epstein-Barr virus glycoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Proteolytic processing of human cytomegalovirus glycoprotein B (gpUL55) is mediated by the human endoprotease furin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Proteolytic processing of human cytomegalovirus glycoprotein B is dispensable for viral growth in culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Constitutive expression of human cytomegalovirus glycoprotein B (gpUL55) with mutagenized carboxy-terminal hydrophobic domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Antibodies to Recombinant-Derived Glycoprotein B after Natural Human Cytomegalovirus Infection Correlate with Neutralizing Activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Crystal structure of the conserved herpesvirus fusion regulator complex gH–gL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cascade of Events Governing Cell-Cell Fusion Induced by Herpes Simplex Virus Glycoproteins gD, gH/gL, and gB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Mapping regions of Epstein-Barr virus (EBV) glycoprotein B (gB) important for fusion function with gH/gL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus glycoproteins gB and gH/gL mediate epithelial cell-cell fusion when expressed either in cis or in trans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus glycoprotein gO complexes with gH/gL, promoting interference with viral entry into human fibroblasts but not entry into epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cytomegalovirus UL131-128 products promote gB conformational transition and gB-gH interaction during entry into endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Protein pUL128 of human cytomegalovirus is necessary for monocyte infection and blocking of migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Two novel spliced genes in human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Distinct glycoprotein O complexes arise in a post-Golgi compartment of cytomegalovirus-infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus TR strain glycoprotein O acts as a chaperone promoting gH/gL incorporation into virions but is not present in virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

A human cytomegalovirus gO-null mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

UL74 of human cytomegalovirus contributes to virus release by promoting secondary envelopment of virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Accumulation of virion tegument and envelope proteins in a stable cytoplasmic compartment during human cytomegalovirus replication: characterization of a potential site of virus assembly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Properties of a human cytomegalovirus-induced protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Catalytic properties of a human cytomegalovirus-induced protein kinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Genomic location of a human cytomegalovirus protein with protein kinase activity (PK68).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus pUL83 stimulates activity of the viral immediate-early promoter through its interaction with the cellular IFI16 protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Major tegument protein pp65 of human cytomegalovirus is required for the incorporation of pUL69 and pUL97 into the virus particle and for viral growth in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus protein pp65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR alpha-chain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cytomegalovirus selectively blocks antigen processing and presentation of its immediate–early gene product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus immediate-early 1 protein facilitates viral replication by antagonizing histone deacetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Binding STAT2 by the acidic domain of human cytomegalovirus IE1 promotes viral growth and is negatively regulated by SUMO.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus IE1 protein elicits a type II interferon-like host cell response that depends on activated STAT1 but not interferon-γ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Disruption of PML-associated nuclear bodies mediated by the human cytomegalovirus major immediate early gene product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

The nuclear domain 10 (ND10) is disrupted by the human cytomegalovirus gene product IE1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING finger-dependent cryptic transactivator function of PML

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Progress toward an elusive goal: current status of cytomegalovirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Preclinical evaluation of an ALVAC (canarypox)--human cytomegalovirus glycoprotein B vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Vaccine prevention of maternal cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Young children as a probable source of maternal and congenital cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Bacterial artificial chromosome clones of viruses comprising the towne cytomegalovirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Open reading frames carried on UL/b' are implicated in shedding and horizontal transmission of rhesus cytomegalovirus in rhesus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

DNA immunization using highly conserved murine cytomegalovirus genes encoding homologs of human cytomegalovirus UL54 (DNA polymerase) and UL105 (helicase) elicits strong CD8 T-cell responses and is protective against systemic challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Cytomegalovirus vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

Proteins associated with purified human cytomegalovirus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

7 January 2021

Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

7 January 2021

Identification and expression of a human cytomegalovirus glycoprotein with homology to the Epstein-Barr virus BXLF2 product, varicella-zoster virus gpIII, and herpes simplex virus type 1 glycoprotein H.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

7 January 2021

Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

7 January 2021

Human cytomegalovirus ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

7 January 2021

Initiation of cytomegalovirus infection at ND10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.056

7 January 2021

10.1016/J.VACCINE.2012.09.056

Identifiers

DOI

1 reference

27 August 2017

1 reference